T Cell–Depleted Partial Matched Unrelated Donor Transplant for Advanced Myeloid Malignancy: KIR Ligand Mismatch and Outcome  by Weisdorf, Daniel et al.
From the 1
State
Louis
5Emo
Philad
Indian
and 9
Resea
Financial d
Correspon
versit
(e-ma
Received O
 2012 Am
1083-8791
doi:10.101T Cell–Depleted Partial Matched Unrelated Donor
Transplant for Advanced Myeloid Malignancy: KIR
Ligand Mismatch and Outcome
Daniel Weisdorf,1 Sarah Cooley,1 Steven Devine,2 Todd A. Fehniger,3 John DiPersio,3
Claudio Anasetti,4 Edmund K. Waller,5 David Porter,6 Sherif Farag,7 William Drobyski,8
Todd Defor,1 Michael Haagenson,9 Julie Curtsinger,1 Jeffrey Miller1To evaluate the applicability of high-dose conditioning, CD34 selection, and enhanced natural killer (NK)
cell alloreactivity reported as promising after haploidentical transplantation, we tested the same strategy
for patients with advanced/high-risk myeloid leukemia lacking either related or well-matched unrelated
donors (URD). In a prospective multicenter clinical trial using pretransplantation conditioning of thiotepa
(5 mg/kg/day 2), fludarabine (40 mg/mg/M2/day 5), and total body radiation (800 cGy) plus thymoglobulin
(2.5 mg/kg/day  2), as well as a CD34 selected filgrastim stimulated peripheral blood graft from a partial
matched URD, we treated 24 patients. The patients (median age 40 [range: 22-61]) were mismatched at 1-
3 of 10 HLA loci with their donors; all were mismatched at HLA-C. Thirty-seven percent were ethnic or racial
minorities. Twenty-one of 24 engrafted promptlywith 1 primary graft failure and 2 early deaths. The cumulative
incidence of grade II-IVacute graft-versus-host disease (aGVHD) (34%, 95% confidence interval [CI], 14-54%),
chronic GVHD (20%, 95% CI, 2%-38%), and relapse (26%, 95% CI, 8%-84%) were unaffected by KIR ligand
donor:recipientmismatch (n5 5) versusKIR ligandmatch (n5 19).Only 3 (12%) had grade III-IVGVHD.Non-
relapse occurred in 17% (95% CI, 30%-31%) by 100 days and in 35% (95% CI, 15%-55%) by 1 year. Two-year
survival and leukemia-free survival were each 40% (95%CI, 21%-59%) andwas similar in KIR ligandmatched or
mismatched patients. Infections, mostly in the first 2 months, were frequent, and were the cause of death in
5 patients (35%of deaths). T cell recovery andNKcell proliferation and functionalmaturationwere not altered
by KIR ligandmatch ormismatch status. For these high-risk patients, this high intensity regimen and T depleted
approachyielded satisfactory outcomes, but logistical difficulties in arrangingURDgrafts for patients with high-
risk, unstable leukemia limited accrual. Improvements in peritransplantation disease control and additional
measures to augment the allogeneic graft-versus-leukemia effect are still required.
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Several strategies, including large-dose stem cell infu-
sions from haploidentical or unrelated donors [1] and
choosing KIR ligand mismatched and thus natural
killer (NK) cell alloreactive donors, have been reported
as important in experience from Perugia using T cell–
depleted grafts, [2,3] although not confirmed in other
studies [4-7]. Additionally, intensive conditioning
and careful patient selection based on performance
status and limited leukemic burden at HCT has
yielded encouraging outcomes [3]. Following unre-
lated donor (URD) HCT, we and others observed
that utilization of donors with the KIR B haplotype
and particularly those expressing favorable KIR loci
have been associated with reduced relapse and im-
proved leukemia-free survival (LFS) [8-12]. To
capitalize on this intensive conditioning regimen and
study the role of KIR ligand mismatch and thus937
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transplantation, we designed a prospective multi-
center trial testing this identical approach using
CD341 selected URD grafts and the value of KIR-
ligand matched versus mismatched URD for patients
lacking bettermatched family orURDs.We report pa-
tients’ outcomes and potential difficulties in applying
this strategy to a broader leukemia population.PATIENTS AND METHODS
Eligible patients were those at participating centers
(Washington University St. Louis; Moffitt Cancer
Center, Tampa; Medical College of Wisconsin; Ohio
State University; University of Pennsylvania; Emory
University; Indiana University; University of
Minnesota)withmyeloidmalignancies includingAML,
chronic myelogenous leukemia (CML), or myelodys-
plastic syndrome (MDS) having either high-risk cyto-
genetic or molecular abnormalities in early remission,
or those with partial remission or advanced disease. Pa-
tients could have anymarrowblast burden, but nomore
than2000/mLcirculating blasts at the timeof transplan-
tation. Additionally, patients needed satisfactorymulti-
organ function, performance status (comorbidity index
#2) [13], and controlled pretransplantation infections
to be eligible for this myeloablative HCT. Active cen-
tral nervous system leukemia was not allowed unless
treated with intrathecal or systemic therapy. Partially
matched URD were used exclusively for this trial, and
thus patients with a closely matched related donor
(HLA identical or 1 locus mismatched) and those with
an HLA allele-matched (or single allele mismatch)
URD were excluded. Donor selection was directed
to identify those with KIR ligand mismatch [1,5,6]
and thus to preferentially choose donor:recipient
combinations with HLA-C mismatch or Cw4, Bw4,
or Bw6 mismatch as available. HLA-A11 alleles were
not considered in the KIR-ligand (KIR-L) matching
algorithm. Other factors for donor selection, including
donor age, cytomegalovirus (CMV) serostatus, ABO
match, and previous alloimmunization through preg-
nancy, were considered individually and not specified
for this multicenter study. Beyond the 24 patients
treated, 6 others consented to participate, but could
not proceed toHCT for various reasons including pro-
gression of leukemia, donor unavailability, or donor
center nonparticipation. Some of these patients later
had a transplantation either off-study or using alternate
techniques; their results are not included.All participat-
ingpatients anddonors exercisedwritten informedcon-
sent for participation. Donor participation included
consent for donating filgrastim-primed peripheral
blood stem cells (PBSC) according to standard donor
center and National Marrow Donor Program (NMDP)
procedures as well as provision of a prefilgrastim donorblood sample used for research studies associated with
the protocol [14,15]. No other donor procedures were
modified for this study. Institutional review boards at
the NMDP and all participating donor and transplant
centers approved the protocol, which was registered
as NCT00392782 at clinical trials.gov.
Pretransplantation conditioning replicated the
regimen originally reported from Perugia [2,3]
including thiotepa (5 mg/kg/day  2, days 28, 27),
fludarabine (40 mg/mg/M2/day  5, days 7 to 23),
and total body irradiation 800 cGy in 1 or 2 fractions
on day 29 (210). The filgrastim-mobilized URD
PBSC grafts were processed at the transplant center
by immunomagnetic bead CD341 cell selection using
the CliniMacs device with procedures approved under
IDE 12840 from the U.S. Food and Drug Administra-
tion for this study. Targeted graft yields were to retain
.50% of the CD341 cells collected and infuse grafts
containing.75%CD341 cells. Postprocessing, grafts
were required to include.2 106CD341 cells/kg and
\3  104 CD31 cells/kg before infusion. Processed
cells were washed and administered intravenously on
day 0 with no additional posttransplantation GVHD
prophylaxis. Rabbit antithymocyte globulin (Thymo-
globulin, Genzyme Inc., Cambridge, MA) was admin-
istered (2.5 mg/kg day 23 and 22) for additional
in vivo T cell depletion and host immunosuppression.
Supportive care included individual room hospitaliza-
tion, growth factor use, antibiotic therapy directed
toward bacterial, fungal, and viral pathogens per insti-
tutional guidelines as well as prospective monitoring
for CMV and Epstein-Barr Virus infections to permit
preemptive antiviral therapy as needed.
Posttransplantation events were prospectively
identified and reported to the central monitoring site,
the University of Minnesota Masonic Cancer Center
Clinical Trials Office. Engraftment was defined as
the first of 3 consecutive measures of an absolute neu-
trophil count .500/mL and platelets .20,000/mL
without a transfusion for 7 days. Acute and chronic
graft-versus-host disease (aGVHD, cGVHD) were re-
ported using conventional definitions. Because some
patients (6 of 24) had transplantation with active leuke-
mia or advanced MDS, documentation of the achieve-
ment of complete remission by day 28 was required.
Subsequent posttransplantation relapse documented
by hematologic, marrow, or extramedullary findings
was calculated using the cumulative incidence method
to treat nonrelapsemortality as a competing risk. Time
to relapse or death (LFS) and overall survival were cal-
culated from the day of transplantation using the
Kaplan-Meier estimator and 95% confidence intervals
derived from the standard errors [16]. The cumulative
incidence calculation [17] was applied for estimating
the probability of aGVHD and cGVHD and relapse
treating nonevent mortality as a competing risk and es-
timating nonrelapse mortality (NRM) treating relapse
Table 1. Patient Demographics
N (%)
Total 24
Male 11 (46%)
Age in years
Median (range), (IQR) 39.7 (21.9-60.5), (29.7-53.0)
Race/ethnicity
Hispanic 2 (8%)
Non-Hispanic White 15 (63%)
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using SAS and R software. Data was retrieved through
the standardized baseline and follow-up reports to the
Center for International Blood and Marrow Trans-
plant Research (CIBMTR) and the NMDP plus sup-
plemental monitoring for serious adverse events and
infections using procedures specified for this prospec-
tive study protocol.African American 6 (25%)
Asian 1 (4%)
Diagnosis
AML 17 (71%)
CR1 10 (42%)
High risk* 6 (25%)
CR2 4 (21%)
Relapse 3 (8%)
MDS (advanced) 3 (13%)
CML 4 (17%)
Chronic phase (CP)1 1 (4%)
Accelerated/CP2 3 (13%)
Karnofsky†
90-100 19 (79%)
60-80 3 (13%)
Pre-HCT fungal infection 3 (13%)
CMV serostatus†
Recipient positive 13 (54%)
Recipient negative/donor positive 3 (13%)
Recipient negative/donor negative 7 (29%)
Weight in kilograms
Median (range) 95 (48-168)
CD34+ cells infused (106/kg)†
Median (range), (IQR) 4.4 (1.2-9.7), (2.9-6.0)
CD3+ cells infused (104/kg)†
Median (range), (IQR) 2.8 (1-8.4), (1.7-4.2)
HLA locus match
7/10 3 (13%)
8/10 12 (50%)
9/10 9 (38%)
HLA mismatch locus
-A 3 (13%)
-B 10 (42%)
-C 24 (100%)
-DRB1 0
-DQB1 5 (21%)
KIR-L
Matched 19 (79%)
Mismatch (graft-versus-host direction) 5 (21%)
CR indicates complete remission; IQR, interquartile range.
*Molecular or cytogenetic high risk.
†With reported data.RESULTS
Details of patients’ demographics, donor match-
ing, diagnosis, and disease status at transplantation
and graft characteristics are shown in Table 1. All 24
patients were adults with a median age of 40, and 13
were females. Seventeen (71%) patients had AML.
Three were in relapse, and 6 had intermediate/high-
grade MDS or CML beyond first chronic phase at
transplantation. Three had pre-HCT fungal respira-
tory tract infections, and 3 had pre-HCT performance
scores of 60-80. Donors and recipients were mis-
matched at 1-3 HLA alleles (63% had 2-3 mismatches
of 10 [HLA-A, -B, -C, -DRB1, -DQB1]). Mismatches
were at HLA-C (n 5 24, 100%); -B (10, 42%), -A (3,
13%), and -DQB1 (5, 21%). Five of 24 (21%) had
KIR ligand mismatch in the donor-versus-host direc-
tion favoring NK cell alloreactivity.
Of the 24 patients, 21 had prompt donor engraft-
ment at a median of 13 days (range: 9-27) post-HCT.
Platelet recovery (to .20,000/mL) occurred in 17 of
23 evaluable at a median of 18 days (range: 12-34)
post-HCT. Primary graft failure occurred in 1 patient
who had active leukemia at transplantation; 2 others
had early deaths. Two patients had secondary donor
cell reinfusions for incomplete hematologic recovery
and/or persistent leukemia, and 1 recovered following
a second allograft. As shown inTable 2, only 10 patients
developed aGVHD(2 hadmaximumgrade I, 5 grade II,
3 grade III-IV). As shown in Figure 1, the cumulative
incidence of grade II-IV aGVHD was 34% (95% con-
fidence interval [CI], 14%-54%). Only 4 (20% (95%
CI, 2%-38%) had developed cGVHD by 1 year post-
HCT. Six had a posttransplantation relapse at a median
of 5 (2.5-11) months posttransplantation. Relapse inci-
dence at 2 years was not lower in recipients of KIR-L
mismatched than KIR-L matched donor grafts (KIR-
L matched: 22% (95% CI 4%-40%); mismatched
40% (95% CI 1%-79), P 5 .82). Transplant-related
NRM(death during continuous posttransplantation re-
mission) occurred in 8 patients, 17% (95% CI, 30%-
31%) by 100 days and 35% (95% CI, 15%-55%) by 1
year. The NRM incidence was similar in recipients
transplanted in remission or during relapse (not shown).
These deaths were attributable to infection (viral
[HHV-6,CMV], candida,Escherichia coli [E. coli]), pneu-
monitis, septic shock, central nervous system injury be-
cause of hypotension plus hypoxia, and renal failure.Infections
Sixteen of 24 patients developed 1 or more grade
3-5 infections followingHCT.These included 16 early
bacterial infections (2 E. coli; 4 Staphylococci; 3 Strepto-
cocci, 5 Enterococci; 1 Bacillus sp.), 8 viral infections
(3 polyomavirus; 4 Herpes simplex; 1 CMV), and
2 systemic fungal infections (both candidemia), plus
later infections as shown in Table 3A. The day 100
cumulative incidence of CMV infection was 42%
(95% CI 22%-62%). One patient had multiorgan
CMV disease; the others were detected in blood alone.
Of these infections, 5 were life threatening and 4 were
the primary attributable causes of death (Table 3B).
Beyond 6months post-HCT, infections were reported
in only a minority of evaluable patients.
Table 2. Outcomes after Allogeneic HCT (N 5 24)
N Died 100-Day Survival 2-Year Survival
Survival 14 71% (53%-89%) 40% (21%-59%)
N events 100-day LFS 2-year PFS
Leukemia-free survival 14 75% (53%-88%) 40% (21%-59%)
100-day relapse 2-year relapse
Relapse/progression 6 8% (0%-19%) 26% (8%-44%)
100-day NRM 1-year NRM
Nonrelapse mortality 8 17% (3%-31%) 34% (15%-53%)
Grade II-IV aGVHD 8 34% (14%-54%)
Maximum grade
aGVHD
N (%)
Grade none 14 (58%)
I 2 (8%)
II 5 (21%)
III 2 (8%)
IV 1 (4%)
N 1-year chronic
GVHD
Chronic GVHD 4 20% (2%-38%)
Shown are the number (%) and Kaplan-Meier (survival, LFS) or cumula-
tive incidence (relapse, GVHD, NRM) estimates of post-HCT events
(695% confidence intervals).
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At median follow-up of 13 (7-37) months, 10 of 24
patients have survived with an estimated 2-year survival
of 40% (95% CI, 21%-59%) (Figure 2A). Relapse was
the primary cause in 6 (43%) deaths (Table 3B). No pa-
tients surviving in remission beyond 12months have had
subsequent posttransplantation relapse. In the 6 patients
with persisting or recurring leukemia post-HCT, the
median survival from HCT is 9 (3-11) months. All 10
of the survivors remain in complete remission, and
thus 2 year LFS is also 40% (95% CI, 21%-59%)
(Figure 2B). Survival and LFS at 2 years were identical
at 47% (95% CI, 24%-67%) for those transplanted in
remission and 20% (95% CI, 1%-58%) for those not
in remission at HCT, P 5 .68. KIR-L mismatch in the
graft-versus-host direction was present in 5 of 24 pa-
tients, but had no notable impact on survival: 3 of 5
KIR-L mismatch recipients have survived (median 13Figure 1. Cumulative incidence of aGVHmonths, range: 12-38) versus 7 of 19 KIR-L matched
(median 13 months, range: 7-36), P5 .29. Similarly, 2-
year LFS was similar in KIR-Lmatched (35% [95%CI,
15%-56%] andKIR-LMM[60%,13%-88%],P5 .63).
Immune Recovery after HCT
To address the hypothesis that KIR-L MM would
enhance alloreactivity, we also monitored lymphoid
phenotypic and functional recovery after HCT. Post-
transplantation recovery of both B cell and T cell sub-
sets were delayed and did not reach donor or recipient
pre-HCT levels by day1360, but did not vary accord-
ing to KIR-L matched versus MM grafts (Figure 2A
and B). NK cell numbers increased early (by day
114) and were sustained until day 1180 when they
reached levels similar to those seen in the donor (and
recipient) pre-HCT (Figure 3). There was no acceler-
ated recovery of any cell subset in HCTs using KIR-L
MM donors (Figure 2A and B). Recovery of KIR1
(.30%) NK cells occurred in one-half of the patients
by day 1180 and was similar in those with KIR-L
match or MM donor grafts (data not shown). NK cell
cytolytic capacity (assessed by K562 cytolysis in vitro,
[Figure 4]) reached normal levels by day 1180 and
was also unaffected by HCT using KIR-L M or MM
donor grafts. Recovery of these educated, KIR1 NK
cells was not, however, associated with better protec-
tion against leukemia relapse, infection, or treatment-
related mortality (data not shown).DISCUSSION
We report LFS in this series of high-risk leukemia
patients receiving CD341 cell-selected grafts from
partially matched URD after myeloablative condition-
ing. Investigators from Perugia reported promising
findings in a series of reports stemming from the early
1990s using this high-intensity conditioning, largeD and cGVHD, relapse, and NRM.
Table 3A. Infections (Severity Grades 3-5*)
N Evaluable Patients with Infections N (%)
First 4 weeks
Bacterial 24 16 (67%)
Gram negative 1
Gram positive 13
C. difficile 2
Viral 8 (33%)
Polyoma 3
HSV 4
CMV 1
Fungal 2 (8%)
Candida 2
5-8 weeks
Bacterial 20 5 (25%)
Gram negative 1
Gram positive 4
Viral 6 (30%)
HSV 1
CMV 3
EBV 1
Adenovirus 1
Fungal 0
9-12 weeks
Bacterial 20 6 (30%)
Gram negative 1
Gram positive 5
Viral 5 (25%)
HSV 0
CMV 4
EBV 0
Adenovirus 1
HHV-6 1
Fungal 2 (10%)
Candida 2
13-24 weeks
Bacterial 16 4 (25%)
Gram negative 0
Gram positive 4
Viral 3 (19%)
HSV 0
CMV 2
EBV 0
Adenovirus 0
HHV-6 1
Fungal 1 (6%)
Yeast, Nos. 1
EBV indicates Epstein-Barr Virus; HSV, herpes simplex virus.
*Grade 3 (requiring parenteral antimicrobial therapy); grade 4 (life
threatening); grade 5 (fatal) infections reported over time.
Figure 2. Survival (A) and leukemia progression-free survival (B) after
partial matched URD HCT.
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graft, preferentially collected from a KIR ligand mis-
matched and thus alloreactive haploidentical donor
[1-3]. In similar patients, they described 28% 5-year
event-free survival, with better results (up to 67%)
for patients treated during remission using NK allor-
eactive donors, but less favorable outcomes for thoseTable 3B. Primary Cause of Death
N (%)
Relapse 6 (43%)
Bacterial infection 1 (7%)
Fungal infection 1 (7%)
Viral infection 2 (14%)
Other infection 1 (7%)
Neurotoxicity (sepsis; hypotension) 2 (14%)
Renal failure 1 (7%)with active relapse (6%-34% based upon donor NK
cell alloreactivity) [3]. Based on these encouraging re-
sults, we tested the identical conditioning regimen, im-
munosuppression, and CD341 graft selection in this
prospective series of high-risk myeloid leukemia
patients lacking an HLA-identical sibling or well-
matched URD. In the current series, we observed fa-
vorable achievement of complete remission, even for
those treated during relapse and modest NRM. LFS
was encouraging, with 40% of patients alive and in re-
mission beyond 2 years posttransplantation, similar to
other reports of PBSC HLA-matched and HLA-C
mismatched transplants [18].
Compared with the Perugia series, these URD re-
cipients were somewhat older, had no exposure to any
tolerizing effects of noninherited maternal antigens,
and would not, of course, have inherited any other im-
munologically pertinent genetic elements that could
modulate the hazards of GVHD in a haploidentical re-
lated donor HCT. Some of these factors may explain,
at least in part, the observed higher rates of GVHD
than those reported from Perugia.
Transplantation for patients with advanced,
high-risk myeloid leukemia remains challenging
[18]. Adverse cytogenetics, advanced remission, or
active leukemia at HCT remain as major barriers to
success [19,20]. A recent CIBMTR report
documented favorable HCT outcomes for AML
patients transplanted during relapse, but only for
younger patients (under age 35) who had low blast
burdens, and HLA-identical siblings or well-matched
URD [19]. However, for older patients or those with
advanced disease, intensified conditioning has not
yielded improved outcomes [19]. In contrast, harness-
ing the potent alloreactivity of the graft either through
T replete orNKcell alloreactive,T cell–depleted grafts
offers somewhat better results [3]. T cell depletion
Figure 3. Lymphocyte recovery after HCT. Circulating lymphocyte subsets (T cells, B cells, NK cells) in KIR-L matched (A) and KIR-L mismatched (B)
HCT. The recovery pattern and timing was similar in both cohorts and recovered to near normal (similar to pre-HCT donor and recipient measures) by
6 to 9 months after HCT. Subset numbers were similar in both cohorts studied. Absolute lymphocyte numbers were not available at all time points; thus,
absolute lymphocyte subset numbers are not shown.
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the favorable impact of NK alloreactivity [21-23].
However, exercising this option for patients with
advanced or unstable leukemia was daunting. Orches-
trating the logistics to enroll patients with suitable per-
formance status and minimal disease burden or
remission was difficult, particularly when coordinating
the timing of transplantation to best meet the patients’
needs. Addionally, the delivered CD34 graft dose is
restricted by donor registry (NMDP) standards, and
thus grafts might be smaller than those received from
haploidentical family donors. We restricted eligibility
for this trial to patients lacking an HLA identical sib-
ling (approximately one-third of patients) or an HLA
allele-matched URD (40%-75% of patients based on
their ethnicity, racial group), leaving only a minority
of patients potentially eligible for consideration
[24,25]. Umbilical cord blood or haploidentical
family transplants may be another option, potentially
more quickly available [26,27], but for haploidentical
transplants, published success beyond the Perugia
experience has been limited [28], but are now being ex-
plored within the Bone Marrow Transplant Clinical
Trials Newwork [29]. Umbilical cord blood grafts
have rarely been used for AML in relapse.Figure 4. Lymphocyte cytolysis of K562 in post-HCT samples. Shown are th
from HCT donor and recipients over time post-HCT. Recovery of lytic activity
ligand matched and mismatched HCT.In this trial, we observed satisfactory clinical results
including some control of active leukemia, but no sug-
gestion that KIR ligand mismatch was associated with
improved outcome or less risk of relapse. Because of
limited accrual, we were unable to definitively address
these questions. Though early but not all reports sug-
gested the possibility [30,31], we did not observe that
KIR-L mismatch was associated with improved NK
reconstitution following transplantation. Similar to
several retrospective analyses [5-7,10,12], our data
suggest that additional factors beyond the KIR ligand
mismatch model are operative in these transplants.
A substantially larger number of subjects, perhaps
with more uniform disease status, will be required to
satisfactorily probe these hypotheses that were derived
from the earlier, large haploidentical HCT experience.
Nonetheless, outcomes in these high-risk and advanced
patients, with limited posttransplantation GVHD-
related morbidity, suggest that elements of this ap-
proach should be further investigated. Enhancements
needed for timely logistics in coordinating donor avail-
ability and patient readiness suitable for unstable, high-
risk AML remain to be refined. Prompt initiation of
search and donor identification soon after diagnosis
can enhance donor availability at the right time to allowe % lysis (effector:target 20:1) of K562 targets by lymphocytes collected
was good beyond day 28 post-HCTand was similar in recipients of KIR-
Biol Blood Marrow Transplant 18:937-943, 2012 943KIR-Ligand Mismatched Unrelated Donor Transplantationpatients to receive a transplant when they best need it.
Further investigations to enhance donor graft alloreac-
tivity mediated either by T cells or NK cells might bet-
ter capitalize on graft-versus-leukemia to limit relapse
and improve survival for high-risk AML.
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